Bicycle Therapeutics plc (BCYC)
Largest Insider Buys in Sector
BCYC Stock Price History Chart
BCYC Stock Performance
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Insider Activity of Bicycle Therapeutics plc
Over the last 12 months, insiders at Bicycle Therapeutics plc have bought $21.23M and sold $1.13M worth of Bicycle Therapeutics plc stock.
On average, over the past 5 years, insiders at Bicycle Therapeutics plc have bought $21.23M and sold $6.61M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP () — $382.15M.
The last purchase of 500,000 shares for transaction amount of $7.67M was made by BAKER BROS. ADVISORS LP () on 2024‑12‑16.
List of Insider Buy and Sell Transactions, Bicycle Therapeutics plc
| 2025-01-06 | Sale | CHIEF ACCOUNTING OFFICER | 2,686 0.0039% | $15.00 | $40,290 | +0.64% | ||
| 2025-01-03 | Sale | CHIEF EXECUTIVE OFFICER | 3,092 0.0044% | $14.75 | $45,607 | -0.07% | ||
| 2025-01-03 | Sale | CHIEF TECHNOLOGY OFFICER | 936 0.0013% | $14.75 | $13,806 | -0.07% | ||
| 2025-01-03 | Sale | CHIEF OPERATING OFFICER | 936 0.0013% | $14.75 | $13,806 | -0.07% | ||
| 2025-01-03 | Sale | CHIEF PROD & SUPPLY CHAIN OFF | 239 0.0003% | $14.75 | $3,525 | -0.07% | ||
| 2025-01-03 | Sale | CHIEF BUSINESS OFFICER | 936 0.0013% | $14.75 | $13,806 | -0.07% | ||
| 2025-01-03 | Sale | CHIEF ACCOUNTING OFFICER | 159 0.0002% | $14.75 | $2,345 | -0.07% | ||
| 2025-01-02 | Sale | CHIEF EXECUTIVE OFFICER | 9,038 0.013% | $14.09 | $127,345 | +3.66% | ||
| 2025-01-02 | Sale | CHIEF TECHNOLOGY OFFICER | 3,287 0.0047% | $14.09 | $46,314 | +3.66% | ||
| 2025-01-02 | Sale | CHIEF OPERATING OFFICER | 4,578 0.0066% | $14.09 | $64,504 | +3.66% | ||
| 2025-01-02 | Sale | CHIEF DEVELOPMENT OFFICER | 4,943 0.0071% | $14.09 | $69,647 | +3.66% | ||
| 2025-01-02 | Sale | CHIEF PROD & SUPPLY CHAIN OFF | 1,879 0.0027% | $14.09 | $26,475 | +3.66% | ||
| 2025-01-02 | Sale | CHIEF BUSINESS OFFICER | 2,583 0.0037% | $14.09 | $36,394 | +3.66% | ||
| 2025-01-02 | Sale | Chief Financial Officer | 1,395 0.002% | $14.09 | $19,656 | +3.66% | ||
| 2025-01-02 | Sale | CHIEF ACCOUNTING OFFICER | 1,750 0.0025% | $14.09 | $24,658 | +3.66% | ||
| 2024-12-16 | 500,000 0.7341% | $15.34 | $7.67M | -3.17% | ||||
| 2024-12-13 | 985,397 1.3409% | $13.76 | $13.56M | +6.30% | ||||
| 2024-11-11 | Sale | CHIEF ACCOUNTING OFFICER | 4,944 0.0073% | $25.13 | $124,248 | -20.02% | ||
| 2024-10-03 | Sale | CHIEF EXECUTIVE OFFICER | 3,212 0.0044% | $22.26 | $71,499 | -7.79% | ||
| 2024-10-03 | Sale | CHIEF TECHNOLOGY OFFICER | 972 0.0013% | $22.26 | $21,637 | -7.79% |
Insider Historical Profitability
| BAKER BROS. ADVISORS LP | 9995274 14.4826% | $13.56 | 2 | 0 | ||
| Lee Kevin | CHIEF EXECUTIVE OFFICER | 491934 0.7128% | $13.56 | 0 | 39 | |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER | 123722 0.1793% | $13.56 | 0 | 10 | |
| Milnes Alistair | CHIEF OPERATING OFFICER | 99788 0.1446% | $13.56 | 0 | 10 | |
| Arroyo Santiago | CHIEF DEVELOPMENT OFFICER | 69057 0.1001% | $13.56 | 0 | 1 | |
| Keen Nicholas | CHIEF SCIENTIFIC OFFICER | 62024 0.0899% | $13.56 | 0 | 16 | |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 55280 0.0801% | $13.56 | 0 | 5 | |
| Crockett Nigel | CHIEF BUSINESS OFFICER | 51053 0.074% | $13.56 | 0 | 13 | |
| Young Alethia | Chief Financial Officer | 45605 0.0661% | $13.56 | 0 | 1 | |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 32146 0.0466% | $13.56 | 0 | 10 | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10 percent owner | 1957961 2.837% | $13.56 | 1 | 0 | <0.0001% |
| HARLAND DEBORAH | director | 1915275 2.7751% | $13.56 | 1 | 0 | <0.0001% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 1910531 2.7682% | $13.56 | 1 | 2 | <0.0001% |
| SVLSF V, LLC | 10 percent owner | 1875637 2.7177% | $13.56 | 1 | 0 | <0.0001% |
| Novartis Bioventures Ltd | 10 percent owner | 1769641 2.5641% | $13.56 | 1 | 0 | <0.0001% |
| Anstey Michael | director | 1751437 2.5377% | $13.56 | 1 | 0 | <0.0001% |
| Cambridge Innovation Capital (Jersey) Ltd | 10 percent owner | 1751437 2.5377% | $13.56 | 1 | 0 | <0.0001% |
| NG CAROLYN | director | 571429 0.828% | $13.56 | 1 | 0 | |
| BINGHAM KATE | director | 38708 0.0561% | $13.56 | 1 | 2 | <0.0001% |
| Smethurst Dominic | Chief Medical Officer | 36699 0.0532% | $13.56 | 0 | 1 | |
| Kalowski Lee | President and CFO | 30309 0.0439% | $13.56 | 0 | 13 | |
| Legault Pierre | director | 0 0% | $13.56 | 0 | 8 |
Institutional Investor Ownership
| Baker Bros Advisors LP | $123.08M | 9.94 | 4.94M | +176.07% | +$78.5M | 0.88 | |
| Deep Track Capital Lp | $86.91M | 7.02 | 3.49M | 0% | +$0 | 0.4 | |
| Paradigm BioCapital Advisors LP | $80.84M | 6.53 | 3.25M | -12.41% | -$11.46M | 2.93 | |
| Armistice Capital Llc | $41.63M | 3.36 | 1.67M | +8.85% | +$3.39M | 0.13 | |
| Tybourne Capital Management HK Ltd | $38.47M | 3.11 | 1.55M | -6.38% | -$2.62M | 6.58 | |
| Morgan Stanley | $37.77M | 3.05 | 1.52M | +47.37% | +$12.14M | <0.01 | |
| First Light Asset Management | $29.71M | 2.4 | 1.19M | -23.05% | -$8.9M | 2.5 | |
| Westfield Capital Management Co Lp | $25.87M | 2.09 | 1.04M | +13.26% | +$3.03M | 0.14 | |
| Polar Capital | $25.01M | 2.02 | 1M | 0% | +$0 | 0.14 | |
| Suvretta Capital Management, LLC | $22.77M | 1.84 | 914,476 | 0% | +$0 | 0.96 | |
| Candriam S C A | $22.14M | 1.79 | 889,258 | +2.3% | +$498,000.00 | 0.14 | |
| RA Capital Management, L.P. | $19.92M | 1.61 | 800,000 | 0% | +$0 | 0.02 | |
| BlackRock | $14.32M | 1.16 | 575,030 | +14.63% | +$1.83M | <0.0001 | |
| AXA | $13.8M | 1.12 | 554,163 | +0.01% | +$1,917.30 | 0.04 | |
| Parkman Healthcare Partners Llc | $13.05M | 1.06 | 524,253 | +67.55% | +$5.26M | 1.63 | |
| Camber Capital Management Lp | $11.21M | 0.91 | 450,000 | 0% | +$0 | 0.4 | |
| Schonfeld Group | $10.48M | 0.85 | 420,800 | +293.27% | +$7.81M | 0.06 | |
| T. Rowe Price | $10M | 0.81 | 401,646 | +45.08% | +$3.11M | <0.01 | |
| Bank of America | $9.88M | 0.8 | 396,812 | -13.98% | -$1.61M | <0.01 | |
| Point72 Asset Management | $8.53M | 0.69 | 342,594 | +51.66% | +$2.91M | 0.01 | |
| Verition Fund Management Llc | $8.49M | 0.69 | 340,866 | -53.97% | -$9.95M | 0.08 | |
| PLATINUM INVESTMENT MANAGEMENT LTD | $8.29M | 0.67 | 333,001 | -8.03% | -$724,067.11 | 0.11 | |
| Kennedy Capital Management Inc | $6.28M | 0.51 | 252,172 | -39.45% | -$4.09M | 0.13 | |
| Helm Capital Management LLC | $5.12M | 0.41 | 205,423 | 0% | +$0 | 0.15 | |
| Duquesne Family Office Llc | $4.74M | 0.38 | 190,200 | New | +$4.74M | 0.13 | |
| Handelsbanken | $4.48M | 0.36 | 179,800 | +28.61% | +$995,995.55 | 0.02 | |
| Renaissance Technologies | $4.13M | 0.33 | 165,700 | +57.06% | +$1.5M | 0.01 | |
| HighVista Strategies | $3.94M | 0.32 | 158,293 | 0% | +$0 | 1.45 | |
| Soleus Capital Management, L.P. | $3.81M | 0.31 | 153,000 | +61.05% | +$1.44M | 0.02 | |
| Voya Investment Management LLC | $3.41M | 0.28 | 136,775 | +20.88% | +$588,262.59 | <0.01 | |
| Legal & General | $3.31M | 0.27 | 133,068 | +0.2% | +$6,538.18 | <0.01 | |
| DAFNA Capital Management, LLC | $3.04M | 0.25 | 122,200 | 0% | +$0 | 0.07 | |
| Trexquant Investment LP | $2.3M | 0.19 | 92,552 | -52.86% | -$2.58M | 0.04 | |
| Ubs Oconnor Llc | $2.12M | 0.17 | 84,980 | +15.46% | +$283,337.10 | 0.1 | |
| Pinnacle Associates, Ltd. | $1.99M | 0.16 | 80,090 | New | +$1.99M | 0.03 | |
| Comerica | $1.96M | 0.16 | 78,770 | -3.76% | -$76,692.00 | 0.01 | |
| Alphacentric Advisors Llc | $1.49M | 0.12 | 60,000 | New | +$1.49M | 0.07 | |
| Citadel Advisors LLC | $1.48M | 0.12 | 59,440 | -79.81% | -$5.85M | <0.01 | |
| Goldman Sachs | $1.38M | 0.11 | 55,450 | New | +$1.38M | <0.0001 | |
| Td Asset Management Inc | $1.37M | 0.11 | 54,986 | +56.27% | +$493,019.86 | <0.01 | |
| L&S Advisors, Inc. | $1.25M | 0.1 | 50,260 | +393.23% | +$997,743.00 | 0.16 | |
| National Bank Of Canada Fi | $1.11M | 0.1 | 48,700 | New | +$1.11M | <0.01 | |
| Two Sigma Advisers LP | $1.16M | 0.09 | 46,600 | -25.09% | -$388,614.30 | <0.01 | |
| Harbor Capital Advisors Inc | $1.08M | 0.09 | 43,480 | +62.92% | +$418,255.20 | 0.14 | |
| SEB | $1.06M | 0.09 | 42,729 | New | +$1.06M | 0.01 | |
| Wexford Capital, LLC | $868,487.00 | 0.07 | 34,879 | 0% | +$0 | 0.19 | |
| Allianz Asset Management Gmbh | $761,940.00 | 0.06 | 30,600 | 0% | +$0 | <0.01 | |
| DekaBank | $700,000.00 | 0.06 | 30,000 | 0% | +$0 | <0.01 | |
| Two Sigma | $711,766.00 | 0.06 | 28,585 | -72.42% | -$1.87M | <0.01 | |
| The Manufacturers Life Insurance Company | $646,354.00 | 0.05 | 25,958 | +97.06% | +$318,346.40 | <0.01 |